Nanoparticles (NP), defined as particles with a diameter less than 100 nm, are known to act more efficient in circulation and uptake by cells than microparticles due to their unique physicochemical properties. In recent decades, NP have emerged as important tools in modern medicine, the use of NP in medical applications has increased markedly with clinical applications ranging from contrast agents in imaging for diagonstic purpose to carriers for drug/vaccine and gene delivery to targeted cells and tissues for therapeutic treatments, even further in theranostic personalised disease management. Although some NP-based medicine (nanomedicine) have received regulatory approval but many more are still in clinical investigation. Despite current intense research in this field, the ways in which the human organs respond to nanoscale particulates are still being defined. NP can vary in composition, size, shape, and surface properties, all have significant impact on the nanoparticles pharmacokinetic, efficacy, safety and targeting benefits. While FDA-approved nanomaterials are mostly polymeric, liposomal, virus-like particles (VLPs) and nanocrystal formulations, there are more micellar, metallic, biocompatible, biodegradable and self-assembled protein-based particles coming through the development process. More complexed platforms incorporating a broadening range of NP types are also being developed. This special issue will focus on recent developments in nanoparticles and their applications in medicine, including but not limited to drug/vaccine delivery, biological imaging, photo thermal therapy, tissue repair, immunoassay, cell separation, cancer diagnosis and treatment, etc., aiming to have better understanding on NP toxicity, biodistributions, clearance and efficacy in modern medicine.
Dr. Sue XiangGuest Editor
biocompatible and biodegradable nanoparticles
cancer diagnosis and therapy
Submission Deadline: 30 June 2020
Manuscripts should be submitted online through Hapres Online Submission System. Please visit Guide for Authors before submitting a manuscript. Authors are encouraged to submit a paper as soon as it is ready and don’t need to wait until the deadline. Submissions will be sent to peer-review in order of arrival. Accepted papers will be published continuously in Med One and then gathered together on the special issue webpage. We welcome Research articles, Review papers and Perspectives. There are no word limits for each article type. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for approval.
Virtual Special Issue (VSI) is a collection of papers centered around a specific topic, led by an expert (Guest Editor) in the field. Virtual Special Issues are an important component of our journal and cover current hot topics within the scope of the journal.
All papers belonging to a Virtual Special Issue will be gathered together on a single webpage. They are published in the regular issues of the journal as soon as publishable, and labeled as belonging to the Virtual Special Issue. A link from each paper will take you to the Virtual Special Issue website.
Submissions to Virtual Special Issues will undergo the same rigorous peer-review process as regular papers submitted to the journal.
Department of Immunology and Pathology, Central Clinical School, Faculty of Medicine and Health Sciences, Monash University, Australia